NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

计划入组 30 人 · 首次发布于 2019 年 10 月 23 日

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

计划入组 39 人 · 首次发布于 2022 年 12 月 1 日

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

计划入组 25 人 · 首次发布于 2020 年 11 月 4 日

IMM-255

GEC-255

Microbiotica Ltd.

United Kingdom

Intravacc B.V.

Denmark

Context Therapeutics

United States

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

REVEAL GENOMICS and Ona Therapeutics Partner to Advance Novel ADC Cancer Treatment with Biomarker Strategy

Ona Therapeutics Appoints ADC Development Veteran Dr. Antoine Yver as Board Chair to Advance Breast Cancer Pipeline